| Dr Shujath A Khan, MD | |
|
8121 National Ave, Suit 401, Midwest City, OK 73110-7530 | |
| (405) 732-6223 | |
| (405) 741-0414 |
| Full Name | Dr Shujath A Khan |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Gastroenterology |
| Location | 8121 National Ave, Midwest City, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568490183 | NPI | - | NPPES |
| 1568490183 | Other | OK | BLUE CROSS BLUE SHIELD |
| 1568490183 | Other | OK | RAILROAD MEDICARE |
| 100018820A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 13081 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shujath A Khan, MD 8121 National Ave, Suit 401, Midwest City, OK 73110-7530 Ph: (405) 732-6223 | Dr Shujath A Khan, MD 8121 National Ave, Suit 401, Midwest City, OK 73110-7530 Ph: (405) 732-6223 |
News Archive
Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
Researchers have developed a faster, cheaper way to coat liquid medication, an invention that could improve how drugs are delivered in the body.
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers without BRCA1 and BRCA2 gene mutations.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
› Verified 5 days ago
Dr. Stephen A Hamilton, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 230 N Midwest Blvd, Midwest City, OK 73110 Phone: 405-737-8455 Fax: 405-739-8707 | |
Dr. Mohammed Naveed Ahmed, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 8121 National Ave Ste 300, Midwest City, OK 73110 Phone: 405-610-3023 Fax: 405-733-0779 | |
Dr. Bereket Alemu, M.D Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9230 E Reno Ave, Suite B, Midwest City, OK 73130 Phone: 405-737-4900 Fax: 405-737-3606 | |
Vaqar Ahmad, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 8121 National Ave, Suite 402, Midwest City, OK 73110 Phone: 405-736-6095 Fax: 405-736-6682 | |
Aneesh Venkat Pakala, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 6951 Se 15th St, Midwest City, OK 73110 Phone: 405-233-0450 Fax: 405-233-0451 | |
Arif A Shakir, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 412 S Air Depot Blvd, Ste B, Midwest City, OK 73110 Phone: 405-737-2800 Fax: 405-737-2858 | |
Dr. Samson Mulu Ambaw, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9230 E. Reno Ave Suite B, Midwest City, OK 73130 Phone: 405-737-4900 Fax: 405-737-3606 |